The Bharat BioTech’s Phase -1 trials shown promising results vaccine was well tolerated in all groups. The COVAXIN is India’s first indigenous vaccine. The phase-1 trials was conducted on 375 volunteers. “The vaccine was well tolerated in all dose groups with no vaccine-related serious adverse events. Interim findings from phase 1 trial of Covaxin: After 1st vaccination, local & systemic adverse events were predominantly mild/moderate in severity & resolved rapidly, without prescribed medication. The most common adverse event was pain at the injection site which resolved spontaneously.” Bharat BioTech said in a research papers
The company has said the majority of mild symptoms have been observed during the study but no major serious adverse effect have been reported.
“Only one serious adverse event was reported that was unrelated to the vaccination,” the company said in the research papers published on https://www.medrxiv.org/content/10.1101/2020.12.11.20210419v1.full.pdf
